Morgan Stanley analyst Tejas Savant lowered the firm’s price target on Personalis (PSNL) to $5 from $11 and keeps an Equal Weight rating on the shares after the company’s guidance fell short on core weakness and interim CEO Aaron Tachibana provided an update to leadership’s strategic priorities. While clinical efforts are on track and a new strategic plan that extends the cash runway is a positive, the expected wind-down of contributions from Natera (NTRA) "further clouds visibility," the firm said.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PSNL:
- Personalis price target lowered to $10 from $13 at H.C. Wainwright
- Personalis reports Q4 EPS (67c), consensus (64c)
- Personalis upgraded to Buy at Needham on cost reductions, biopharma potential
- Personalis upgraded to Buy from Hold at Needham
- Personalis, Moderna announce new agreement to leverage NeXT Platform
